prescription drug abuse 4: 349
scheduled drug 4: 170
stimulants 4: 350
substance abuse 4:311, 313
substance abuse treatment
4:351, 352
tolerance 4: 354
withdrawal syndrome 4: 354
Addison’s disease 2:67, 256;
3:106–107, 106 t
adrenal insufficiency 3: 109
aldosterone 3: 112
cortisol 3: 116
Cushing’s syndrome 3: 118
hyperaldosteronism 3: 137
hypercalciuria 3: 197
hyponatremia 3: 143
adenocarcinoma 2: 208 , 366;
3:17–18, 28, 40, 90, 91, 104 See
alsotumor, cancerous
Adenocard. Seeadenosine
adenoid hypertrophy 1:7–8
adenoids 1:7–8, 58
adenoma 3:107. See alsotumor,
noncancerous
acromegaly 3: 104
adrenal glands 3: 109
Cushing’s syndrome 3: 117
hyperaldosteronism 3: 137
hypernatremia 3: 138
hyperparathyroidism 3: 138
MEN 3: 151
adenoma-to-carcinoma transition
2: 366
acromegaly 3: 106
adenoma 3: 107
adrenal glands 3: 109
colorectal cancer 3: 31
esophageal cancer 3: 41
FAP 3: 43
HNPCC 3: 58
intestinal polyp 3: 64
stomach cancer 3: 91
adenomyosis 3:241
adenosine (Adenocard) 2:77, 84t
adenosine triphosphate (ATP)
3:128; 4: 134
adenovirus 2: 221 , 306
ADH. Seeantidiuretic hormone
ADHD. Seeattention deficit
hyperactivity disorder
adhesive capsulitis 1:298–299, 353
adipose (fat) cells 3:126, 156, 160,
249
adipose tissue 1:128, 134–135,
333–334
adolescence 1:313; 4: 215 , 240,
240 t,250, 292
adoption 3:241–242, 281 , 289
adrenal cortex 3:99, 106, 111
adrenal glands 3:107–109, 108 t,
109 t
ACTH 3: 110
Addison’s disease 3: 106
adrenal insufficiency 3: 109
androgens 3: 113
cortisol 3: 116
CRH 3: 116
DHEA 3: 119
dopamine 3: 124
endocrine system 3: 99
epinephrine 3: 125
estrogens 3: 126
hyperaldosteronism 3: 136
hyperkalemia 3: 138
norepinephrine 3: 152
pheochromocytoma 3: 154
progesterone 3: 156
renin 3: 158
testosterone 3: 160
urinary system 3: 171
adrenal insufficiency 3: 106 ,
109–110, 110 t,131, 137, 138,
143, 154
adrenocorticotropic hormone
(ACTH) 3:101, 106, 109, 110,
112, 116, 117
adult acne. Seerosacea
adult survivors of childhood cancer
2:366–367
adverse drug reaction 1:365, 384;
4:148–149, 148 t, 149 , 163 , 164 ,
171 , 318
Advil. Seeibuprofen
AED. Seeautomated external
defibrillator
aerobic bacteria 2:308, 346
aerobic capacity 2:9, 73, 123;
4:213, 213 t
aerobic exercise 4: 214
blood doping 4: 324
conditioning 4: 217
disability and exercise 4: 220
endurance 4: 220
fitness level 4: 222
physical activity
recommendations 4: 228
strength 4: 232
training 4: 233
walking for fitness 4: 235
aerobic exercise 1:63; 2:27, 30, 97,
194; 4:213–214, 214 taerobic capacity 4: 213
cross training 4: 219
physical activity
recommendations 4: 228
resistance exercise 4: 229
strength 4: 232
training 4: 233
walking for fitness 4: 235
aerobic fitness 2:9, 9 t
aging and pulmonary changes
2: 183
asthma 2: 188
breathing exercises 2: 194
cardiac capacity 2: 27
cardiac output 2: 30
COPD 2: 201
dyspnea 2: 203
heart rate 2: 60
AFP. Seealpha fetoprotein
African Americans 2:64, 165, 293,
295, 296; 4:48, 255
age 2:220, 222; 4: 278
age-related macular degeneration
(ARMD) 1: 69 , 70–71,73, 78;
4:60, 79, 80, 107
age spots. Seelentigines
aging, cancer and 2:365; 3:91, 251,
253, 255, 256, 274, 275
aging, cardiovascular changes that
occur with 2:9–10, 27 , 34 , 49 ,
98; 4: 16
aging, changes in pain perception
that occur with 1:364–365
aging, changes in physical ability
and fitness needs that occur with
4:214–215
aging, changes in the blood and
lymph that occur with
2:123–124
aging, effects on drug metabolism
and drug response 1:364–365;
4:149–150
aging, effects on immune response
2:239, 275
aging, endocrine changes that occur
with 3: 109 , 110–111,163, 164;
4:76, 88
aging, gastrointestinal changes that
occur with 3:10, 32 , 35 , 46 , 50 ,
58 , 64
aging, integumentary changes that
occur with 1:134–135,210–211
aging, musculoskeletal changes that
occur with 1:298–299, 299–300,
326–327, 341–342, 345–347,350;
4: 72444 Index